TAK 14.62 ▲ 1.25% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Takeda Pharmaceutical Li...

    NYSE: TAK · Real-Time Price · USD
    14.62
    0.18 (1.25%)
    At close: Oct 03, 2025, 3:59 PM
    14.70
    0.55%
    After-hours: Oct 03, 2025, 06:19 PM EDT
    1.25%
    Bid 14.38
    Market Cap 46.17B
    Revenue (ttm) 4,480.2B
    Net Income (ttm) 136.88B
    EPS (ttm) 0.29
    PE Ratio (ttm) 50.41
    Forward PE 0.18
    Analyst n/a
    Dividends $0.6
    Ask 14.88
    Volume 2,572,409
    Avg. Volume (20D) 3,749,122
    Open 14.45
    Previous Close 14.44
    Day's Range 14.45 - 14.62
    52-Week Range 12.80 - 15.69
    Beta 0.27
    Ex-Dividend Date Mar 31, 2025

    About TAK

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TAK
    Website n/a
    Full Company Profile

    Next Earnings Release

    Takeda Pharmaceutical Limited is scheduled to release its earnings on Oct 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 months ago
    -5.25%
    Takeda Pharmaceutical shares are trading lower fol... Unlock content with Pro Subscription
    7 months ago
    +2.98%
    Takeda Pharmaceutical shares are trading higher after the company announced topline results from phase 3 verify study of rusfertide in patients with polycythemia vera.
    news image

    2 days ago · reuters.com

    Takeda Pharmaceutical to exit cell therapy research

    Japanese drugmaker Takeda Pharmaceutical said on Wednesday it will discontinue its cell therapy research and look for a partner to advance candidates under development.

    news image

    2 days ago · reuters.com

    Bristol Myers, Takeda to pool data for AI-based drug discovery

    Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and develop...

    news image

    1 week ago · seekingalpha.com

    Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually

    Takeda (TAK) offers a compelling investment case with six late-stage therapies targeting $20 billion in peak sales by 2030-31. TAK's pipeline includes first-in-class and best-in-class candidates, but ...

    news image

    1 week ago · businesswire.com

    20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries

    OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE: TAK) today committed JPY 4.6 billion (approx. USD 32.1 million) to four new Global Corporate Social Responsibility (CSR) part...

    news image

    2 weeks ago · fool.com

    5 Best High-Yield Dividend Stocks to Buy Now

    High-yield dividend stocks entice investors with payouts two to four times higher than the S&P 500's 1.4% average yield. But high yield often signals trouble -- sluggish growth, stretched payout ratio...

    news image

    2 weeks ago · businesswire.com

    Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran

    OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and VELA Transport today announced their business partnership, with Takeda set to become the first biopharmaceutical compan...

    news image

    3 weeks ago · businesswire.com

    Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that Rhonda Pacheco, most recently group vice president of U.S. Cardiometabolic Health at Eli Lilly, will join Takeda, eff...

    news image

    3 weeks ago · seekingalpha.com

    Takeda Pharmaceutical Company Limited (TAK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

    Takeda Pharmaceutical Company Limited (NYSE:TAK ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Milano Furuta - CFO & Director Conference C...

    news image

    3 weeks ago · seekingalpha.com

    Takeda Pharmaceutical Company Limited (TAK) Oveporexton (TAK-861) Investor Call On Phase 3 Narcolepsy Type 1 Data Presented At World Sleep 2025 (Transcript)

    Takeda Pharmaceutical Company Limited (NYSE:TAK ) Oveporexton (TAK-861) Investor Call on Phase 3 Narcolepsy Type 1 Data Presented at World Sleep 2025 Company Participants Christopher David O'Reilly - ...

    news image

    3 weeks ago · businesswire.com

    Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

    SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a...

    Add to Watchlist